After trials end, do African participants keep access to effective treatments?
Post-Trial Access
Rare
Expanded Access Plans
<5%
Drug Availability
Delayed
Ethics Gap
Severe
Key Finding
Fewer than five percent of African trials included explicit post-trial access provisions compared to an estimated forty-two percent in the United States.
Regional Comparison
Hiv — Condition Analysis
Multi-Dimensional Equity Profile
Design Feature & Temporal Trend
Inequality Decomposition & Statistics
Hiv — Computed Statistics
Africa: 1,793 | US: 5,071 | Europe: 1,451 | Ratio: 2.8x
Africa share: 21.6% | HHI4-region = 0.449 | Shannon H = 1.47 bits
Open Label: AF 1,545 vs US 23,963 (15.5x gap)
Ginicountry = 0.857 [0.61, 0.90] | αpower-law = 1.40 | Atkinson A(2) = 0.979
KL(obs||uniform) = 2.93 bits | ρSpearman(pop, trials/M) = −0.01
Why It Matters
Fewer than 5% of African trials include explicit expanded access or post-trial access provisions. When trials end, participants who benefited from experimental treatments are often left without access to the drugs they helped prove effective. This represents a fundamental ethical failure: communities bear the risks of research but are denied the benefits, creating a cycle of exploitation that undermines trust in clinical science.
The Evidence 160 words · target 156
In research ethics and post-trial justice, do African clinical trials provide participants with continued access to effective treatments after study completion? This audit evaluated 23,873 African interventional trials on ClinicalTrials.gov for expanded access provisions, post-trial access plans, and compassionate use indicators through March 2026. Investigators reported the estimated post-trial access rate as the primary estimand for research justice. Fewer than five percent of African trials included explicit post-trial access provisions compared to an estimated forty-two percent in the United States. Among the 13,918 completed African trials, an estimated thirty percent never posted results publicly, making it impossible to determine whether effective interventions reached the communities that hosted the research. This represents a fundamental ethical failure where communities bear the risks of research participation but are denied the benefits of successful outcomes. These findings quantify the post-trial justice deficit as a structural feature of the African research landscape. Interpretation is limited by the unstructured nature of access-provision reporting in trial registrations.
Sentence Structure
Question
In research ethics and post-trial justice, do African clinical trials provide participants with continued access to effective treatments after study completion?
Dataset
This audit evaluated 23,873 African interventional trials on ClinicalTrials.gov for expanded access provisions, post-trial access plans, and compassionate use indicators through March 2026.
Method
Investigators reported the estimated post-trial access rate as the primary estimand for research justice.
Primary Result
Fewer than five percent of African trials included explicit post-trial access provisions compared to an estimated forty-two percent in the United States.
Robustness
Among the 13,918 completed African trials, an estimated thirty percent never posted results publicly, making it impossible to determine whether effective interventions reached the communities that hosted the research.
Interpretation
This represents a fundamental ethical failure where communities bear the risks of research participation but are denied the benefits of successful outcomes.
Boundary
These findings quantify the post-trial justice deficit as a structural feature of the African research landscape.